Aeolus Pharmaceuticals Initiates Second Study Of AEOL 10150 As A Countermeasure To Radiation Exposure In Mice

Aeolus Pharmaceuticals, Inc. (OTC Bulletin Board: AOLS) announced the initiation of a second study, in mice, to determine the optimal length of treatment with AEOL 10150 when used as a countermeasure to Acute Radiation Syndrome (ARS) in the lungs. This study, led by Zeljko Vujaskovic, M.D. Ph.D.